$370.78
Value $30.6B
LH and LLY stock compared: price, dividend, valuation and results, from SEC filings.
$370.78
Value $30.6B
$1,382.75
Value $1.30T
Labcorp (LH) has a market value of $30.6B and Eli Lilly and Company (LLY) $1.30T. Over the last year, with dividends, LH moved +43.3% and LLY +36.2%. The P/E is 30.4 for LH and 47.3 for LLY. Dividend yield: LH 0.78%, LLY 0.46%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
LH$30.6B
LLY$1.30T
LLY is 43 times LH
Revenue, 12 months
LH$14.6B
LLY$86.5B
LLY is 5.9 times LH
Net income, 12 months
LH$1.0B
LLY$27.6B
LLY is 27 times LH
Operating margin
LH10.3%
LLY–
ROIC
LH8.2%
LLY35.5%
27.3 points apart
P/E
LH30.4
LLY47.3
LLY is 1.6 times LH
Dividend yield
LH0.8%
LLY0.5%
0.3 points apart
5-year return
LH+57.1%
LLY+452.8%
395.7 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
LH+57.1%
LLY+452.8%
| Period | LHWith dividends | LLYWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | +43.3%Price +41.9% | +36.2%Price +35.3% |
| 3 years since November 17, 2023 | +80.7%+21.8% a yearPrice +75.1% | +138.4%+33.6% a yearPrice +133.7% |
| 5 years since November 17, 2021 | +57.1%+9.5% a yearPrice +49.0% | +452.8%+40.8% a yearPrice +429.4% |
| 10 years since November 18, 2016 | +261.3%+13.7% a yearPrice +242.5% | +1,997.9%+35.6% a yearPrice +1,703.5% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
LHLabcorpLLYEli Lilly and Company
| Price | $370.78 | $1,382.75 |
|---|---|---|
| Market value | $30.6B | $1.30T |
| Enterprise value (EV) | $36.2B | $1.35T |
| P/E | 30.4 | 47.3 |
| P/E, 5-year median | 24.0 | 49.9 |
| P/B | 3.5 | 32.4 |
| EV/EBIT | 24.1 | 38.8 |
| Free cash flow yield | 4.2% | 1.5% |
| Revenue, 12 months | $14.6B | $86.5B |
|---|---|---|
| Net income, 12 months | $1.0B | $27.6B |
| Free cash flow, 12 months | $1.3B | $19.7B |
| Earnings per share, 12 months | $12.19 | $30.81 |
| Revenue growth, year on year | 7.2% | 44.7% |
| Revenue growth a year, past | -0.0%over 5 years | +21.6%over 5 years |
| EPS growth a year, past | -8.0%over 5 years | +27.6%over 5 years |
| Gross margin | 29.0% | 83.6% |
|---|---|---|
| Operating margin | 10.3% | – |
| Net margin | 6.9% | 31.9% |
| ROIC | 8.2% | 35.5% |
| ROE | 11.5% | 88.6% |
| Cash | $262M | $4.9B |
|---|---|---|
| Total debt | $6.8B | $49.5B |
| Net debt / EBITDA | 2.6 | 1.2 |
| Interest cover | 6.5× | 38.9× |
| Dividend yield | 0.8% | 0.5% |
|---|---|---|
| Dividend per share, 12 months | $2.88 | $6.34 |
| Dividend growth a year, past | – | +15.2%over 5 years |
| Buyback yield | 1.5% | 0.3% |
| Shareholder yield | 2.3% | 0.8% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Eli Lilly and Company ($1.30T) is about 42.7 times Labcorp ($30.6B), at today's prices.
Since November 18, 2016, LH's price moved +242.5% and LLY's +1,703.5%. With dividends: LH +261.3% (+13.7% a year), LLY +1,997.9% (+35.6% a year). Past returns do not predict future ones.
The dividend yield at today's price is 0.78% for Labcorp and 0.46% for Eli Lilly and Company. Over the last twelve months they paid $2.88 and $6.34 per share.
At today's price, the P/E is 30.4 for LH and 47.3 for LLY. The median of the last five years was 24.0 and 49.9, which shows where each stands against its own past.
Over the last twelve months, the net margin was 6.9% for Labcorp and 31.9% for Eli Lilly and Company, and the operating margin 10.3% and –. Revenue was $14.6B and $86.5B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.